$AIM News
Last published 1d ago
- 1d agoAIMAIM ImmunoTech to Present in the Webull Corporate Connect Webinar SeriesGlobeNewswireLive webcast on Thursday, November 12, 2026 at 2:40 PM ET
- 6d agoAIMAIM ImmunoTech Highlights Ampligen® Opportunity to Potentially Extend Benefits of RAS-Targeted Therapies in Pancreatic CancerGlobeNewswireNew investor presentation outlines scientific rationale for combining Ampligen’s immune-stimulating activity with daraxonrasib’s targeted RAS inhibition to potentially prolong clinical benefit Previously reported
- 1mo agoAIMAIM ImmunoTech’s Strategy to Address Immune Resistance in Pancreatic Cancer Featured in BioTuesdaysGlobeNewswireCEO interview explores Ampligen’s potential to extend survival and improve quality of life as AIM advances toward pivotal development Access the article here OCALA, Fla., Oct. 07, 2026 (GLOBE NEWSWIRE) -- AIM
- 2mo agoAIMAIM ImmunoTech Highlights Scientific Rationale, Supportive Data and Continued Advancement of Ampligen® in Pancreatic Cancer in New CEO Corner VideoGlobeNewswireCompany continues to advance Phase 2 DURIPANC study and broader clinical strategy evaluating Ampligen’s potential to reshape the tumor microenvironment and enhance checkpoint inhibition Access it here OCALA, Fla.,
- 2mo agoAIMAIM ImmunoTech Significantly Expands Ampligen® Global Patent Estate with Long COVID Protection Across Europe and the United Kingdom Through 2041GlobeNewswirePatent protections establish long-duration intellectual property coverage for Ampligen across major European markets and the United Kingdom Latest milestone further strengthens AIM’s expanding global Ampligen patent
- 2mo agoAIMAIM ImmunoTech Secures Broad U.S. Patent for Rintatolimod (Ampligen®) Used in Combination with Pembrolizumab (Keytruda®), Expanding Oncology IP Protection for Ampligen Through 2039GlobeNewswireOCALA, Fla., Aug. 31, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today announced that the United States Patent and Trademark Office has granted a patent covering
- 2mo agoAIMAIM ImmunoTech Participates in the Virtual Investor ‘Why Now’ On-Demand ConferenceGlobeNewswireVideo webcast now available here OCALA, Fla., Aug. 27, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today announced that it participated in the Virtual Investor
- 2mo agoAIMAKTXCNSPDARE+5JTC Team Releases Virtual Investor "Why Now" On-Demand Conference Featuring Nine Public Company CEOsACCESS NewswireNine CEOs. Nine investment stories. 60 seconds each to answer the question that matters most to investors: Why now?On-demand video series gives investors rapid access to company leadership, recent milestones, upcoming
- 3mo agoAIMAIM ImmunoTech CEO Highlights Biodefense and Military Force Protection in Newly Published ‘Breaking Defense’ ArticleGlobeNewswireArticle by CEO Thomas K. Equels calls for proactive evaluation of broad-spectrum antiviral countermeasures before novel viral threats emerge Highlights Company’s investigational drug Ampligen® (rintatolimod) and its
- 3mo agoAIMAIM ImmunoTech Reports Second Quarter 2026 Financial Results and Highlights Significant Operational Execution Advancing Ampligen® Toward Planned Phase 3 Development in Pancreatic CancerGlobeNewswireCompleted Enrollment and Ampligen Dosing in Metastatic Pancreatic Cancer Phase 2 Trial, Positioning Company for Key Clinical Milestones Through Early 2027 Pancreatic Cancer Remains Strategic Priority as AIM Advances
- 3mo agoAIMAIM ImmunoTech Ahead of Schedule on ‘Last Dose’ DURIPANC Critical Clinical Inflection PointGlobeNewswireOCALA, Fla., Aug. 03, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today announced that the final subject has received their last dose of Ampligen® (rintatolimod)
- 4mo agoAIMAIM ImmunoTech Announces Release of New CEO Corner Segment Highlighting Growing Momentum Across Pancreatic Cancer ProgramGlobeNewswireAccess it here OCALA, Fla., July 07, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today announced the release of its latest CEO Corner segment, featuring Chief
- 4mo agoAIMAIM ImmunoTech Accelerates Toward Potential Pivotal Pancreatic Cancer Program as Ampligen Continues to Advance Through Key Clinical MilestonesGlobeNewswireOCALA, Fla., June 24, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today highlighted the significant progress achieved across its pancreatic cancer development
- 4mo agoAIMBULLAIM ImmunoTech to Present in the Webull Corporate Connect Webinar SeriesGlobeNewswireOCALA, Fla., June 22, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today announced that it will present in the Webull Corporate Connect Webinar Series being held
- 4mo agoAIMAIM ImmunoTech Achieves Clinical Milestone as Final Subject Receives First Dose in Phase 2 DURIPANC Study in Metastatic Pancreatic CancerGlobeNewswireOCALA, Fla., June 18, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today announced that the final subject has received their first dose in the Phase 2 DURIPANC clinical trial
- 4mo agoAIMAIM ImmunoTech Regains NYSE American Compliance, Company Resolves Stockholder Equity DeficiencyGlobeNewswireOCALA, Fla., June 15, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM," or the "Company"), an immuno-pharma company focused on the development of therapeutics to treat multiple types of cancers, immune
- 5mo agoAIMAIM ImmunoTech Announces $2.65 Million Financing Priced At-Market under NYSE American RulesGlobeNewswireOCALA, Fla., June 09, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company"), today announced that it has entered into definitive agreements for a registered direct offering and concurrent
- 5mo agoAIMAIM ImmunoTech Reports Positive Mid-Year Interim Clinical Progress from Phase 2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca's Imfinzi® (durvalumab) for the Treatment of Pancreatic CancerGlobeNewswireOCALA, Fla., June 08, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today reported positive progress in a mid-year update from the ongoing Phase 2 clinical study evaluating AIM's drug
- 5mo agoAIMAIM ImmunoTech Releases Virtual Investor 'What This Means' Video Segment Discussing Ampligen's Potential in Ebola Virus Disease PreparednessGlobeNewswireVideo segment examines current Ebola outbreak concerns, unmet need surrounding the Bundibugyo strain and Ampligen's previously published antiviral research Discussion highlights Ampligen's immune-modulating mechanism,
- 5mo agoAIMAIM ImmunoTech Completes Phase 2 DURIPANC Enrollment Milestone Ahead of Schedule, Advancing Ampligen Toward Critical Pancreatic Cancer Clinical MilestonesGlobeNewswireOCALA, Fla., June 01, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today announced a significant milestone in its pancreatic cancer development program, with enrollment of the final
- 5mo agoAIMAIM ImmunoTech Announces Emerging Ebola Opportunity for Ampligen Amid Escalating Global Health Concerns and WHO Emergency DeclarationGlobeNewswirePreviously published Biosafety Level 4 pre-clinical study showed 100% survival with early treatment following infection in a mouse model following lethal doses of Ebola Company to release Virtual Investor "Ebola: What
- 5mo agoAIMAIM ImmunoTech Announces $2.4 Million Financing, Including Concurrent Registered Direct Offering and Private PlacementGlobeNewswireOCALA, Fla., May 20, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company", today announced that it has entered into definitive agreements for a registered direct offering priced at-the-market
- 5mo agoAIMAIM ImmunoTech Announces Significant Increase in Stockholder Equity and Extension of Promissory Note Maturity Date to June 2027, Enhancing Financial Flexibility and Supporting Strategic Clinical PrioritiesGlobeNewswireOCALA, Fla., May 19, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today announced a significant increase in stockholder equity and that the Company has entered into Amendment #2 to
- 6mo agoAIMAIM ImmunoTech Posts Virtual Investor Key Opinion Leader Segment Spotlighting Ampligen Breakthrough Data in Pancreatic CancerGlobeNewswirePositive Data from Named Patient Program and Positive Interim Data from Ongoing Phase 2 Clinical Trial Segment featuring Professor Doctor Casper H.J. van Eijck, Professor and Pancreato-biliary Surgeon at Erasmus MC
- 6mo agoAIMAIM ImmunoTech, Inc. Announces Exercise of Warrants for Approx. $4.2 Million in Gross ProceedsGlobeNewswireOCALA, Fla., May 08, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech, Inc. (NYSEAM:AIM) ("AIM ImmunoTech" or the "Company"), a late-stage biotechnology company focused on the discovery and development of drugs for the
- 6mo agoAIMAIM ImmunoTech Announces 50% Objective Response Rate (ORR) in UPMC Recurrent Ovarian Cancer Phase 2 Clinical Trial, Suggesting Breakthrough Combination PotentialGlobeNewswireOCALA, Fla., May 07, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today announced the Final Primary Endpoint Report on Objective Response Rate data from a University of Pittsburgh
- 6mo agoAIMAIM ImmunoTech Enters Pivotal Value Inflection Phase with Planned Phase 3 Study of Ampligen® in Pancreatic Cancer, Backed by Positive Clinical Signals, Orphan Drug Status, and Global IPGlobeNewswireCompany to participate in Live Virtual Investor Closing Bell segment today, April 16th at 4:00 PM ET; Register for the event here OCALA, Fla., April 16, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM"
- 7mo agoAIMAIM ImmunoTech Provides Routine Update on Annual FilingsGlobeNewswireOCALA, Fla., April 13, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today advised that its audited consolidated financial statements for the fiscal year ended December 31, 2025,
- 7mo agoAIMAIM ImmunoTech to Participate in Live Virtual Investor Closing Bell EventGlobeNewswireLive video webcast with Tom Equels, Chief Executive Officer of AIM ImmunoTech, on Thursday, April 16th at 4:00 PM ET Register for the event here OCALA, Fla., April 09, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc.
- 8mo agoAIMAIM ImmunoTech Announces Closing of its Rights OfferingGlobeNewswireOCALA, Fla., March 06, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) – AIM ImmunoTech Inc. ("AIM" or the "Company"), an immuno-pharma company focused on the research and development of its lead product,
- 8mo agoAIMAIM ImmunoTech Announces Expiration and Preliminary Results of its Rights Offering for Aggregate Gross Proceeds of $1.8 MillionGlobeNewswireOCALA, Fla., March 04, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) – AIM ImmunoTech Inc. ("AIM" or the "Company"), an immuno-pharma company focused on the research and development of its lead product,
- 8mo agoAIMAIM ImmunoTech Signs Agreement for Planning of a Proposed Phase 3 Clinical Trial of Ampligen in the Treatment of Late-Stage Pancreatic CancerGlobeNewswireOCALA, Fla., March 02, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today announced an agreement with the PPD™ clinical research business of Thermo Fisher Scientific to design
- 8mo agoAIMAIM ImmunoTech Reminds Stockholders of March 3, 2026 Expiration Date and Updates Terms of Previously Announced Rights OfferingGlobeNewswireOCALA, Fla., Feb. 27, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) – AIM ImmunoTech Inc. ("AIM" or the "Company"), an immuno-pharma company focused on the research and development of its lead product,
- 8mo agoAIMAIM ImmunoTech Announces Extension of Subscription Period of its Previously Announced Rights Offering to March 3, 2026GlobeNewswireOCALA, Fla., Feb. 25, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) – AIM ImmunoTech Inc. ("AIM" or the "Company"), an immuno-pharma company focused on the research and development of its lead product,
- 8mo agoAIMAIM ImmunoTech Announces Planned Milestones in the Ongoing Phase 2 Trial of Ampligen and AstraZeneca's Durvalumab in the Treatment of Metastatic Pancreatic CancerGlobeNewswireOCALA, Fla., Feb. 23, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today announced milestones in the expected timeline for the ongoing Phase 2 clinical study evaluating AIM's drug
- 9mo agoAIMCORRECTION: AIM ImmunoTech Announces Commencement of Rights OfferingGlobeNewswireThis press release is issued solely to correct a date from an AIM press release dated February 11, 2026. The Subscription Rights will expire if they are not exercised by 5:00 p.m., Eastern Time, on February 27, 2026, the
- 9mo agoAIMAIM ImmunoTech to Participate in Live Virtual Investor Closing Bell EventGlobeNewswireLive video webcast with Tom Equels, Chief Executive Officer of AIM ImmunoTech, on Thursday, February 19th at 4:00 PM ET Event to focus on lead program, Ampligen, for treatment of pancreatic cancer OCALA, Fla., Feb.
- 9mo agoAIMAIM ImmunoTech Announces Commencement of Rights OfferingGlobeNewswireOCALA, Fla., Feb. 11, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) – AIM ImmunoTech Inc. ("AIM" or the "Company"), an immuno-pharma company focused on the research and development of its lead product,
- 9mo agoAIMAKTXBULLDCOY+2JTC Team Companies to Present in Webull Corporate Connect Webinar Series Happening February 10-11, 2026ACCESS NewswireRegister for the two-day virtual event hereFRENCHTOWN, NJ / ACCESS Newswire / February 9, 2026 / JTC Team , a fully integrated corporate communications and investor relations firm, today announced its companies
- 9mo agoAIMAIM ImmunoTech to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull FinancialGlobeNewswireLive video webcast on Wednesday, February 11th at 1:40 PM EST OCALA, Fla., Feb. 06, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company"), today that it will participate in the Corporate
- 9mo agoAIMAIM ImmunoTech Reports Positive Year-End Interim Clinical Progress from Phase 2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca's Imfinzi® (durvalumab) for the Treatment of Pancreatic CancerGlobeNewswireOCALA, Fla., Feb. 05, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today reported positive data in a year-end update from the ongoing Phase 2 clinical study evaluating AIM's drug
- 9mo agoAIMAIM ImmunoTech Announces Changes to Key Dates and Terms Related to Announced Rights OfferingGlobeNewswireOCALA, Fla., Jan. 27, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) – AIM ImmunoTech Inc. ("AIM" or the "Company"), an immuno-pharma company focused on the research and development of therapeutics to treat
- 9mo agoAIMAIM ImmunoTech Announces Key Dates and Terms Related to Announced Rights OfferingGlobeNewswireOCALA, Fla., Jan. 23, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) – AIM ImmunoTech Inc. ("AIM" or the "Company"), an immuno-pharma company focused on the research and development of therapeutics to treat
- 10mo agoAIMAIM ImmunoTech Announces Stock DividendGlobeNewswireOCALA, Fla., Dec. 30, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today announced a stock dividend of one share of common stock for every 1,000 shares of outstanding common stock
- 11mo agoONCYAIMAVBPMRUS+1Immunotherapy Breakthroughs Turn Cold GI Tumors Hot as Market Tops $443BPR NewswireUSANewsGroup.com News Commentary – Gastrointestinal cancers that once resisted checkpoint inhibitors are finally responding to novel combination...
- 11mo agoAIMAIM ImmunoTech Announces Release of the Next CEO Corner SegmentGlobeNewswireOCALA, Fla., Dec. 10, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today announced the next CEO Corner segment has been published on the Company's website. In this latest CEO Corner
- 11mo agoAIMAIM ImmunoTech to Participate in Live 'Fireside' Chat on Virtual Investor Closing Bell SeriesGlobeNewswireOCALA, Fla., Dec. 01, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") announced today that Thomas K. Equels, MS JD, Chief Executive Officer of AIM will participate in the Virtual
- 11mo agoAIMAIM ImmunoTech Reports Third Quarter 2025 Financial Results and Highlights Continued Progress Across Pipeline with Strategic Focus on Pancreatic Cancer Clinical ProgramGlobeNewswireOCALA, Fla., Nov. 18, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company"), today provided a business update and reported its financial results for the third quarter 2025. "The third
- 1y agoAIMAIM ImmunoTech Details New UPMC Abstract on Completed Clinical Trial Involving Ampligen's Synergistic Potential in the Treatment of Advanced Recurrent Ovarian CancerGlobeNewswireOCALA, Fla., Nov. 10, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today detailed a recent abstract containing data from the completed Phase 2 advanced recurrent ovarian cancer
- 1y agoAIMAIM ImmunoTech Announces Late Breaking Abstract from University of Pittsburgh Medical Center Accepted for Presentation at the 40th Annual Society for Immunotherapy of Cancer (SITC) MeetingGlobeNewswireOCALA, Fla., Nov. 04, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today announced that data from the completed Phase 2 cisplatin-resistant advanced recurrent ovarian cancer clinical